The global market for Non-selective PDE Inhibitors was valued at US$ 278 million in the year 2024 and is projected to reach a revised size of US$ 387 million by 2031, growing at a CAGR of 4.6% during the forecast period.

Non-selective PDE Inhibitors Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Non-selective PDE Inhibitors competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Non-selective PDE inhibitors represent an earlier generation of phosphodiesterase inhibitors that act on multiple PDE isoenzymes simultaneously, thereby enhancing both cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) signaling pathways. Representative compounds include theophylline and Ibudilast, which have historically been used in the treatment of asthma, chronic obstructive pulmonary disease (COPD), cardiovascular conditions, and as central nervous system stimulants. Their upstream raw materials are primarily synthetic small molecules such as xanthine derivatives and methylxanthines, with supply chains concentrated among chemical and pharmaceutical intermediates manufacturers in Europe, North America, and Asia. Key suppliers include multinational API producers and specialized fine chemical companies.

On the downstream side, the major customers of non-selective PDE inhibitors are pharmaceutical firms and generic drug manufacturers, who market them as either prescription or over-the-counter medications. Additionally, due to compounds like caffeine being widely utilized in functional beverages and dietary supplements, clients also extend to food & beverage producers and nutraceutical companies. Despite being gradually replaced by more selective PDE inhibitors due to safety and efficacy considerations, non-selective PDE inhibitors retain a role in legacy therapies, cost-sensitive healthcare markets, and high-volume OTC applications, maintaining a stable but specialized demand base.

In 2024, the global average price of non-selective PDE inhibitors is approximately USD 0.053 per unit (where "unit" refers to the smallest packaged dosage form, such as a tablet, capsule, or vial), with total sales reaching about 5.245 billion units.

North American market for Non-selective PDE Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Non-selective PDE Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Non-selective PDE Inhibitors include Kyorin Holdings, Senju Pharmaceutical, Handok, Endo International, iNova Pharmaceuticals, Alembic, Mundipharma, Mitsubishi Tanabe Pharma, Glenmark Pharmaceuticals, Reyoung Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Non-selective PDE Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-selective PDE Inhibitors.

The Non-selective PDE Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Non-selective PDE Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Non-selective PDE Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Non-selective PDE Inhibitors Market Report

Report Metric	Details
Report Name	Non-selective PDE Inhibitors Market
Accounted market size in year	US$ 278 million
Forecasted market size in 2031	US$ 387 million
CAGR	4.6%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Theophylline Ibudilast Other
Segment by Application	Hospital Clinic Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Kyorin Holdings, Senju Pharmaceutical, Handok, Endo International, iNova Pharmaceuticals, Alembic, Mundipharma, Mitsubishi Tanabe Pharma, Glenmark Pharmaceuticals, Reyoung Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Non-selective PDE Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Non-selective PDE Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Non-selective PDE Inhibitors Market growing?

Ans: The Non-selective PDE Inhibitors Market witnessing a CAGR of 4.6% during the forecast period 2025-2031.

What is the Non-selective PDE Inhibitors Market size in 2031?

Ans: The Non-selective PDE Inhibitors Market size in 2031 will be US$ 387 million.

Who are the main players in the Non-selective PDE Inhibitors Market report?

Ans: The main players in the Non-selective PDE Inhibitors Market are Kyorin Holdings, Senju Pharmaceutical, Handok, Endo International, iNova Pharmaceuticals, Alembic, Mundipharma, Mitsubishi Tanabe Pharma, Glenmark Pharmaceuticals, Reyoung Pharmaceutical

What are the Application segmentation covered in the Non-selective PDE Inhibitors Market report?

Ans: The Applications covered in the Non-selective PDE Inhibitors Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Non-selective PDE Inhibitors Market report?

Ans: The Types covered in the Non-selective PDE Inhibitors Market report are Theophylline, Ibudilast, Other

1 Non-selective PDE Inhibitors Market Overview

1.1 Product Definition

1.2 Non-selective PDE Inhibitors by Type

1.2.1 Global Non-selective PDE Inhibitors Market Value Comparison by Type (2024 VS 2031)

1.2.2 Theophylline

1.2.3 Ibudilast

1.2.4 Other

1.3 Non-selective PDE Inhibitors by Application

1.3.1 Global Non-selective PDE Inhibitors Market Value by Application (2024 VS 2031)

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Others

1.4 Global Non-selective PDE Inhibitors Market Size Estimates and Forecasts

1.4.1 Global Non-selective PDE Inhibitors Revenue 2020-2031

1.4.2 Global Non-selective PDE Inhibitors Sales 2020-2031

1.4.3 Global Non-selective PDE Inhibitors Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Non-selective PDE Inhibitors Market Competition by Manufacturers

2.1 Global Non-selective PDE Inhibitors Sales Market Share by Manufacturers (2020-2025)

2.2 Global Non-selective PDE Inhibitors Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Non-selective PDE Inhibitors Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Non-selective PDE Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Non-selective PDE Inhibitors, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Non-selective PDE Inhibitors, Product Type & Application

2.7 Global Key Manufacturers of Non-selective PDE Inhibitors, Date of Enter into This Industry

2.8 Global Non-selective PDE Inhibitors Market Competitive Situation and Trends

2.8.1 Global Non-selective PDE Inhibitors Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Non-selective PDE Inhibitors Players Market Share by Revenue

2.8.3 Global Non-selective PDE Inhibitors Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Non-selective PDE Inhibitors Market Scenario by Region

3.1 Global Non-selective PDE Inhibitors Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Non-selective PDE Inhibitors Sales by Region: 2020-2031

3.2.1 Global Non-selective PDE Inhibitors Sales by Region: 2020-2025

3.2.2 Global Non-selective PDE Inhibitors Sales by Region: 2026-2031

3.3 Global Non-selective PDE Inhibitors Revenue by Region: 2020-2031

3.3.1 Global Non-selective PDE Inhibitors Revenue by Region: 2020-2025

3.3.2 Global Non-selective PDE Inhibitors Revenue by Region: 2026-2031

3.4 North America Non-selective PDE Inhibitors Market Facts & Figures by Country

3.4.1 North America Non-selective PDE Inhibitors Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Non-selective PDE Inhibitors Sales by Country (2020-2031)

3.4.3 North America Non-selective PDE Inhibitors Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Non-selective PDE Inhibitors Market Facts & Figures by Country

3.5.1 Europe Non-selective PDE Inhibitors Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Non-selective PDE Inhibitors Sales by Country (2020-2031)

3.5.3 Europe Non-selective PDE Inhibitors Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Non-selective PDE Inhibitors Market Facts & Figures by Region

3.6.1 Asia Pacific Non-selective PDE Inhibitors Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Non-selective PDE Inhibitors Sales by Region (2020-2031)

3.6.3 Asia Pacific Non-selective PDE Inhibitors Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Non-selective PDE Inhibitors Market Facts & Figures by Country

3.7.1 Latin America Non-selective PDE Inhibitors Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Non-selective PDE Inhibitors Sales by Country (2020-2031)

3.7.3 Latin America Non-selective PDE Inhibitors Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Non-selective PDE Inhibitors Market Facts & Figures by Country

3.8.1 Middle East and Africa Non-selective PDE Inhibitors Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Non-selective PDE Inhibitors Sales by Country (2020-2031)

3.8.3 Middle East and Africa Non-selective PDE Inhibitors Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Non-selective PDE Inhibitors Sales by Type (2020-2031)

4.1.1 Global Non-selective PDE Inhibitors Sales by Type (2020-2025)

4.1.2 Global Non-selective PDE Inhibitors Sales by Type (2026-2031)

4.1.3 Global Non-selective PDE Inhibitors Sales Market Share by Type (2020-2031)

4.2 Global Non-selective PDE Inhibitors Revenue by Type (2020-2031)

4.2.1 Global Non-selective PDE Inhibitors Revenue by Type (2020-2025)

4.2.2 Global Non-selective PDE Inhibitors Revenue by Type (2026-2031)

4.2.3 Global Non-selective PDE Inhibitors Revenue Market Share by Type (2020-2031)

4.3 Global Non-selective PDE Inhibitors Price by Type (2020-2031)

5 Segment by Application

5.1 Global Non-selective PDE Inhibitors Sales by Application (2020-2031)

5.1.1 Global Non-selective PDE Inhibitors Sales by Application (2020-2025)

5.1.2 Global Non-selective PDE Inhibitors Sales by Application (2026-2031)

5.1.3 Global Non-selective PDE Inhibitors Sales Market Share by Application (2020-2031)

5.2 Global Non-selective PDE Inhibitors Revenue by Application (2020-2031)

5.2.1 Global Non-selective PDE Inhibitors Revenue by Application (2020-2025)

5.2.2 Global Non-selective PDE Inhibitors Revenue by Application (2026-2031)

5.2.3 Global Non-selective PDE Inhibitors Revenue Market Share by Application (2020-2031)

5.3 Global Non-selective PDE Inhibitors Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Kyorin Holdings

6.1.1 Kyorin Holdings Company Information

6.1.2 Kyorin Holdings Description and Business Overview

6.1.3 Kyorin Holdings Non-selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Kyorin Holdings Non-selective PDE Inhibitors Product Portfolio

6.1.5 Kyorin Holdings Recent Developments/Updates

6.2 Senju Pharmaceutical

6.2.1 Senju Pharmaceutical Company Information

6.2.2 Senju Pharmaceutical Description and Business Overview

6.2.3 Senju Pharmaceutical Non-selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Senju Pharmaceutical Non-selective PDE Inhibitors Product Portfolio

6.2.5 Senju Pharmaceutical Recent Developments/Updates

6.3 Handok

6.3.1 Handok Company Information

6.3.2 Handok Description and Business Overview

6.3.3 Handok Non-selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Handok Non-selective PDE Inhibitors Product Portfolio

6.3.5 Handok Recent Developments/Updates

6.4 Endo International

6.4.1 Endo International Company Information

6.4.2 Endo International Description and Business Overview

6.4.3 Endo International Non-selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Endo International Non-selective PDE Inhibitors Product Portfolio

6.4.5 Endo International Recent Developments/Updates

6.5 iNova Pharmaceuticals

6.5.1 iNova Pharmaceuticals Company Information

6.5.2 iNova Pharmaceuticals Description and Business Overview

6.5.3 iNova Pharmaceuticals Non-selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.5.4 iNova Pharmaceuticals Non-selective PDE Inhibitors Product Portfolio

6.5.5 iNova Pharmaceuticals Recent Developments/Updates

6.6 Alembic

6.6.1 Alembic Company Information

6.6.2 Alembic Description and Business Overview

6.6.3 Alembic Non-selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Alembic Non-selective PDE Inhibitors Product Portfolio

6.6.5 Alembic Recent Developments/Updates

6.7 Mundipharma

6.7.1 Mundipharma Company Information

6.7.2 Mundipharma Description and Business Overview

6.7.3 Mundipharma Non-selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Mundipharma Non-selective PDE Inhibitors Product Portfolio

6.7.5 Mundipharma Recent Developments/Updates

6.8 Mitsubishi Tanabe Pharma

6.8.1 Mitsubishi Tanabe Pharma Company Information

6.8.2 Mitsubishi Tanabe Pharma Description and Business Overview

6.8.3 Mitsubishi Tanabe Pharma Non-selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Mitsubishi Tanabe Pharma Non-selective PDE Inhibitors Product Portfolio

6.8.5 Mitsubishi Tanabe Pharma Recent Developments/Updates

6.9 Glenmark Pharmaceuticals

6.9.1 Glenmark Pharmaceuticals Company Information

6.9.2 Glenmark Pharmaceuticals Description and Business Overview

6.9.3 Glenmark Pharmaceuticals Non-selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Glenmark Pharmaceuticals Non-selective PDE Inhibitors Product Portfolio

6.9.5 Glenmark Pharmaceuticals Recent Developments/Updates

6.10 Reyoung Pharmaceutical

6.10.1 Reyoung Pharmaceutical Company Information

6.10.2 Reyoung Pharmaceutical Description and Business Overview

6.10.3 Reyoung Pharmaceutical Non-selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Reyoung Pharmaceutical Non-selective PDE Inhibitors Product Portfolio

6.10.5 Reyoung Pharmaceutical Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Non-selective PDE Inhibitors Industry Chain Analysis

7.2 Non-selective PDE Inhibitors Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Non-selective PDE Inhibitors Production Mode & Process Analysis

7.4 Non-selective PDE Inhibitors Sales and Marketing

7.4.1 Non-selective PDE Inhibitors Sales Channels

7.4.2 Non-selective PDE Inhibitors Distributors

7.5 Non-selective PDE Inhibitors Customer Analysis

8 Non-selective PDE Inhibitors Market Dynamics

8.1 Non-selective PDE Inhibitors Industry Trends

8.2 Non-selective PDE Inhibitors Market Drivers

8.3 Non-selective PDE Inhibitors Market Challenges

8.4 Non-selective PDE Inhibitors Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Senju Pharmaceutical

Handok Inc.

Endo International

iNova Pharmaceuticals

Alembic

Mundipharma

Mitsubishi Tanabe Pharma

Glenmark Pharmaceuticals

ReYoung Pharmaceutical

Kyorin Holdings

List of Tables

Table 1. Global Non-selective PDE Inhibitors Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Non-selective PDE Inhibitors Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Non-selective PDE Inhibitors Market Competitive Situation by Manufacturers in 2024

Table 4. Global Non-selective PDE Inhibitors Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Non-selective PDE Inhibitors Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Non-selective PDE Inhibitors Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Non-selective PDE Inhibitors Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Non-selective PDE Inhibitors Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Non-selective PDE Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Non-selective PDE Inhibitors, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Non-selective PDE Inhibitors, Product Type & Application

Table 12. Global Key Manufacturers of Non-selective PDE Inhibitors, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Non-selective PDE Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-selective PDE Inhibitors as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Non-selective PDE Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Non-selective PDE Inhibitors Sales by Region (2020-2025) & (K Units)

Table 18. Global Non-selective PDE Inhibitors Sales Market Share by Region (2020-2025)

Table 19. Global Non-selective PDE Inhibitors Sales by Region (2026-2031) & (K Units)

Table 20. Global Non-selective PDE Inhibitors Sales Market Share by Region (2026-2031)

Table 21. Global Non-selective PDE Inhibitors Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Non-selective PDE Inhibitors Revenue Market Share by Region (2020-2025)

Table 23. Global Non-selective PDE Inhibitors Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Non-selective PDE Inhibitors Revenue Market Share by Region (2026-2031)

Table 25. North America Non-selective PDE Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Non-selective PDE Inhibitors Sales by Country (2020-2025) & (K Units)

Table 27. North America Non-selective PDE Inhibitors Sales by Country (2026-2031) & (K Units)

Table 28. North America Non-selective PDE Inhibitors Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Non-selective PDE Inhibitors Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Non-selective PDE Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Non-selective PDE Inhibitors Sales by Country (2020-2025) & (K Units)

Table 32. Europe Non-selective PDE Inhibitors Sales by Country (2026-2031) & (K Units)

Table 33. Europe Non-selective PDE Inhibitors Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Non-selective PDE Inhibitors Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Non-selective PDE Inhibitors Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Non-selective PDE Inhibitors Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Non-selective PDE Inhibitors Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Non-selective PDE Inhibitors Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Non-selective PDE Inhibitors Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Non-selective PDE Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Non-selective PDE Inhibitors Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Non-selective PDE Inhibitors Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Non-selective PDE Inhibitors Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Non-selective PDE Inhibitors Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Non-selective PDE Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Non-selective PDE Inhibitors Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Non-selective PDE Inhibitors Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Non-selective PDE Inhibitors Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Non-selective PDE Inhibitors Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Non-selective PDE Inhibitors Sales (K Units) by Type (2020-2025)

Table 51. Global Non-selective PDE Inhibitors Sales (K Units) by Type (2026-2031)

Table 52. Global Non-selective PDE Inhibitors Sales Market Share by Type (2020-2025)

Table 53. Global Non-selective PDE Inhibitors Sales Market Share by Type (2026-2031)

Table 54. Global Non-selective PDE Inhibitors Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Non-selective PDE Inhibitors Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Non-selective PDE Inhibitors Revenue Market Share by Type (2020-2025)

Table 57. Global Non-selective PDE Inhibitors Revenue Market Share by Type (2026-2031)

Table 58. Global Non-selective PDE Inhibitors Price (US$/Unit) by Type (2020-2025)

Table 59. Global Non-selective PDE Inhibitors Price (US$/Unit) by Type (2026-2031)

Table 60. Global Non-selective PDE Inhibitors Sales (K Units) by Application (2020-2025)

Table 61. Global Non-selective PDE Inhibitors Sales (K Units) by Application (2026-2031)

Table 62. Global Non-selective PDE Inhibitors Sales Market Share by Application (2020-2025)

Table 63. Global Non-selective PDE Inhibitors Sales Market Share by Application (2026-2031)

Table 64. Global Non-selective PDE Inhibitors Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Non-selective PDE Inhibitors Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Non-selective PDE Inhibitors Revenue Market Share by Application (2020-2025)

Table 67. Global Non-selective PDE Inhibitors Revenue Market Share by Application (2026-2031)

Table 68. Global Non-selective PDE Inhibitors Price (US$/Unit) by Application (2020-2025)

Table 69. Global Non-selective PDE Inhibitors Price (US$/Unit) by Application (2026-2031)

Table 70. Kyorin Holdings Company Information

Table 71. Kyorin Holdings Description and Business Overview

Table 72. Kyorin Holdings Non-selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 73. Kyorin Holdings Non-selective PDE Inhibitors Product

Table 74. Kyorin Holdings Recent Developments/Updates

Table 75. Senju Pharmaceutical Company Information

Table 76. Senju Pharmaceutical Description and Business Overview

Table 77. Senju Pharmaceutical Non-selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 78. Senju Pharmaceutical Non-selective PDE Inhibitors Product

Table 79. Senju Pharmaceutical Recent Developments/Updates

Table 80. Handok Company Information

Table 81. Handok Description and Business Overview

Table 82. Handok Non-selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 83. Handok Non-selective PDE Inhibitors Product

Table 84. Handok Recent Developments/Updates

Table 85. Endo International Company Information

Table 86. Endo International Description and Business Overview

Table 87. Endo International Non-selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 88. Endo International Non-selective PDE Inhibitors Product

Table 89. Endo International Recent Developments/Updates

Table 90. iNova Pharmaceuticals Company Information

Table 91. iNova Pharmaceuticals Description and Business Overview

Table 92. iNova Pharmaceuticals Non-selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 93. iNova Pharmaceuticals Non-selective PDE Inhibitors Product

Table 94. iNova Pharmaceuticals Recent Developments/Updates

Table 95. Alembic Company Information

Table 96. Alembic Description and Business Overview

Table 97. Alembic Non-selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 98. Alembic Non-selective PDE Inhibitors Product

Table 99. Alembic Recent Developments/Updates

Table 100. Mundipharma Company Information

Table 101. Mundipharma Description and Business Overview

Table 102. Mundipharma Non-selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 103. Mundipharma Non-selective PDE Inhibitors Product

Table 104. Mundipharma Recent Developments/Updates

Table 105. Mitsubishi Tanabe Pharma Company Information

Table 106. Mitsubishi Tanabe Pharma Description and Business Overview

Table 107. Mitsubishi Tanabe Pharma Non-selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 108. Mitsubishi Tanabe Pharma Non-selective PDE Inhibitors Product

Table 109. Mitsubishi Tanabe Pharma Recent Developments/Updates

Table 110. Glenmark Pharmaceuticals Company Information

Table 111. Glenmark Pharmaceuticals Description and Business Overview

Table 112. Glenmark Pharmaceuticals Non-selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 113. Glenmark Pharmaceuticals Non-selective PDE Inhibitors Product

Table 114. Glenmark Pharmaceuticals Recent Developments/Updates

Table 115. Reyoung Pharmaceutical Company Information

Table 116. Reyoung Pharmaceutical Description and Business Overview

Table 117. Reyoung Pharmaceutical Non-selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 118. Reyoung Pharmaceutical Non-selective PDE Inhibitors Product

Table 119. Reyoung Pharmaceutical Recent Developments/Updates

Table 120. Key Raw Materials Lists

Table 121. Raw Materials Key Suppliers Lists

Table 122. Non-selective PDE Inhibitors Distributors List

Table 123. Non-selective PDE Inhibitors Customers List

Table 124. Non-selective PDE Inhibitors Market Trends

Table 125. Non-selective PDE Inhibitors Market Drivers

Table 126. Non-selective PDE Inhibitors Market Challenges

Table 127. Non-selective PDE Inhibitors Market Restraints

Table 128. Research Programs/Design for This Report

Table 129. Key Data Information from Secondary Sources

Table 130. Key Data Information from Primary Sources

Table 131. Authors List of This Report

List of Figures

Figure 1. Product Picture of Non-selective PDE Inhibitors

Figure 2. Global Non-selective PDE Inhibitors Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Non-selective PDE Inhibitors Market Share by Type: 2024 & 2031

Figure 4. Theophylline Product Picture

Figure 5. Ibudilast Product Picture

Figure 6. Other Product Picture

Figure 7. Global Non-selective PDE Inhibitors Market Value by Application (2020-2031) & (US$ Million)

Figure 8. Global Non-selective PDE Inhibitors Market Share by Application: 2024 & 2031

Figure 9. Hospital

Figure 10. Clinic

Figure 11. Others

Figure 12. Global Non-selective PDE Inhibitors Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Non-selective PDE Inhibitors Market Size (2020-2031) & (US$ Million)

Figure 14. Global Non-selective PDE Inhibitors Sales (2020-2031) & (K Units)

Figure 15. Global Non-selective PDE Inhibitors Average Price (US$/Unit) & (2020-2031)

Figure 16. Non-selective PDE Inhibitors Report Years Considered

Figure 17. Non-selective PDE Inhibitors Sales Share by Manufacturers in 2024

Figure 18. Global Non-selective PDE Inhibitors Revenue Share by Manufacturers in 2024

Figure 19. Global 5 and 10 Largest Non-selective PDE Inhibitors Players: Market Share by Revenue in Non-selective PDE Inhibitors in 2024

Figure 20. Non-selective PDE Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 21. Global Non-selective PDE Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 22. North America Non-selective PDE Inhibitors Sales Market Share by Country (2020-2031)

Figure 23. North America Non-selective PDE Inhibitors Revenue Market Share by Country (2020-2031)

Figure 24. United States Non-selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 25. Canada Non-selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 26. Europe Non-selective PDE Inhibitors Sales Market Share by Country (2020-2031)

Figure 27. Europe Non-selective PDE Inhibitors Revenue Market Share by Country (2020-2031)

Figure 28. Germany Non-selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. France Non-selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. U.K. Non-selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Italy Non-selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Russia Non-selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Asia Pacific Non-selective PDE Inhibitors Sales Market Share by Region (2020-2031)

Figure 34. Asia Pacific Non-selective PDE Inhibitors Revenue Market Share by Region (2020-2031)

Figure 35. China Non-selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Japan Non-selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. South Korea Non-selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. India Non-selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Australia Non-selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. China Taiwan Non-selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Southeast Asia Non-selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Latin America Non-selective PDE Inhibitors Sales Market Share by Country (2020-2031)

Figure 43. Latin America Non-selective PDE Inhibitors Revenue Market Share by Country (2020-2031)

Figure 44. Mexico Non-selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Brazil Non-selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Argentina Non-selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Colombia Non-selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Middle East and Africa Non-selective PDE Inhibitors Sales Market Share by Country (2020-2031)

Figure 49. Middle East and Africa Non-selective PDE Inhibitors Revenue Market Share by Country (2020-2031)

Figure 50. Turkey Non-selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Saudi Arabia Non-selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. UAE Non-selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Global Sales Market Share of Non-selective PDE Inhibitors by Type (2020-2031)

Figure 54. Global Revenue Market Share of Non-selective PDE Inhibitors by Type (2020-2031)

Figure 55. Global Non-selective PDE Inhibitors Price (US$/Unit) by Type (2020-2031)

Figure 56. Global Sales Market Share of Non-selective PDE Inhibitors by Application (2020-2031)

Figure 57. Global Revenue Market Share of Non-selective PDE Inhibitors by Application (2020-2031)

Figure 58. Global Non-selective PDE Inhibitors Price (US$/Unit) by Application (2020-2031)

Figure 59. Non-selective PDE Inhibitors Value Chain

Figure 60. Channels of Distribution (Direct Vs Distribution)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions